Principles of and Advances in Immunoglobulin Replacement Therapy for Primary Immunodeficiency

Immunology and Allergy Clinics of North America

Volumn 28, Issue 2, 2008, Pages 413-437

  Berger, Melvin ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; ANTISERUM; CARIMMUNE NF; CORTICOSTEROID; FLEBOGAMMA DIF; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PRIVIGEN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANXIETY; ANXIETY DISORDER; ARTHRALGIA; ASEPTIC MENINGITIS; BACKACHE; CHEST TIGHTNESS; CHILL; DISEASE CONTROL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG MONITORING; DRUG TOLERABILITY; EPIDEMIC; FLUSHING; FOOD AND DRUG ADMINISTRATION; HEPATITIS C; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN REPLACEMENT THERAPY; IMMUNOTHERAPY; INFECTION; KIDNEY FAILURE; LUNG INJURY; MENINGISM; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYALGIA; PRIORITY JOURNAL; REVIEW; RIGOR; RISK FACTOR; SIDE EFFECT; TACHYCARDIA; THROMBOSIS; UNITED KINGDOM; UNITED STATES; VIRUS TRANSMISSION;

HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INJECTIONS, SUBCUTANEOUS;

EID: 42049096072     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2008.01.008     Document Type: Review

References (55)

1. von Behring E. Serum therapy in therapeutics and medical science. Nobel Lecture, December 12, 1901. Available at: http://www.nobelprize.org/nobel_prizes/medicine/laureates/1901/behring-lecture.html. Accessed February 29, 2008.
2. Bruton O. Agammaglobulinemia. Pediatrics 9 (1952) 722-728
3. MRC Working Party on Hypogammaglobulinaemia, Hypogammaglobulinaemia in the United Kingdom (1971), Her Majesty's Stationery Office, London
4. US SARS. Compliance program guidance manual. Chapter 42-blood and blood products inspection of source plasma establishments, brokers, testing laboratories, and contractors - 7342.002. Available at:. http://www.fda.gov/cber/cpg/7342002bld.htm#p6 Accessed January 1, 2008
5. US SARS. Guide to inspections of source plasma establishments. Available at:. http://www.fda.gov/ora/inspect_ref/igs/Source_Plasma/default.htm Accessed January 1, 2008
6. Oncley J.L., Melin M., Richert D.A., et al. The separation of the antibodies. isoagglutinins, prothrombin, plasmonogen and beta-lipoprotein into subfractions of human plasma. J Am Chem Soc 71 (1949) 541-550
7. US FDA. Guidance for Industry: safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. Available at:. http://www.fda.gov/cber/gdlns/igivimmuno.htm Accessed July 1, 2008
8. Renal insufficiency and failure associated with immune globulin intravenous therapy-United States, 1985-1998. MMWR Morb Mortal Wkly Rep 48 (1999) 518-521
9. U.S. Food and Drug Administration. Center for Biologics Evaluation and Research. Important safety information on interference with blood glucose measurement following use of parenteral maltose/parenteral galactose/oral xylose-containing products. Available at:. http://www.fda.gov/cber/safety/maltose110405.htm Accessed January 1, 2008
10. Biesert L. Virus validation studies of immunoglobulin preparations. Clin Exp Rheumatol 14 Suppl 15 (1996) S47-S52
11. Horowitz B., Wiebe M.E., Lippin A., et al. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion 25 (1985) 516-522
12. Buckley R. Diagnostic and clinical care guidelines for primary immunodeficiency diseases (2006), Immune Deficiency Foundation, Towson (MD). Available at: www.primaryimmune.org Accessed February 29, 2008
13. Bonilla F.A., Bernstein I.L., Khan D.A., et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 94 5 Suppl 1 (2005) S1-S63
14. Agarwal S., and Cunningham-Rundles C. Assessment and clinical interpretation of reduced IgG values. Ann Allergy Asthma Immunol 99 (2007) 281-283
15. Paris K., and Sorensen R.U. Assessment and clinical interpretation of polysaccharide antibody responses. Ann Allergy Asthma Immunol 99 (2007) 462-464
16. Chouksey A, Berger M. Evaluation of antibody responses to protein antigens. Ann Allergy Asthma Immunol;99:(in press).
17. Fasth A. European Society for Immune Deficiency. Budapest, Hungary, October 2006.
18. Newburger J.W., and Fulton D.R. Kawasaki disease. Curr Opin Pediatr 16 (2004) 508-514
19. Orange J.S., Hossny E.M., Weiler C.R., et al. Use of intravenous immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol 117 (2006) S525-S553
20. Berger M., Pinciaro P.J., et al. Safety, efficacy and pharmacokinetics of Flebogamma 5% for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 24 (2004) 389-396
21. Burks A.W., Sampson H.A., and Buckley R.H. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 314 (1986) 560-564
22. Pierce L.R., and Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 17 (2003) 241-254
23. Mankarious S., Lee M., Fischer S., et al. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med 112 (1988) 634-640
24. Ballow M., Berger M., Bonilla F.A., et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox Sang 84 (2003) 202-210
25. Church J.A., Leibl H., and Stein M.R. US-PID-IGIV 10% -Study Group. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol 26 (2006) 388-395
26. Ochs H.D., and Pinciaro P.J. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 24 (2004) 309-314
27. Andressen I., Kovarik J.M., Spycher M., et al. Product equivalence study comparing the tolerability, pharmacokinetics and pharmacodynamics of various human IgG formulations. J Clin Pharmacol 40 (2000) 722-730
28. Berger M., Cupps T.R., and Fauci A.S. Immunoglobulin replacement by slow subcutaneous infusion. Ann Intern Med 98 (1980) 55-56
29. Ugazio A.G., Duse M., and Re R. Subcutaneous Infusions of gammaglobulin in management of agammaglobulinemia. Lancet I (1982) 226
30. Roord J.J., Van der Meer J.W.M., Kuis M., et al. Home treatment in patients with antibody deficiency by slow subcutaneous infusion of gammaglobulin. Lancet I (1982) 689-690
31. Berger M., Cupps T.R., and Fauci A.S. High dose immunoglobulin replacement therapy during pregnancy. J Am Med Assoc 247 (1982) 2824-2825
32. Berger M., Duff K., and Beal C. Information for patients: pumps and needles used for Subcu IgG. Available at:. http://www.rainbowbabies.org/subcu Accessed January 1, 2008
33. National Institutes of Health Clinical Center Nurses patient information publications. Giving a subcutaneous injection. Available at:. www.cc.nih.gov/ccc/patient_education/pepubs/subq.pdf Accessed January 1, 2008
34. Chouksey A., Duff K., Wasserbauer N., et al. Subcutaneous IgG replacement therapy with preparations currently available in the US for IV or IM use: reasons and regimens. Allergy, asthma and Clinical Immunology 1 (2005) 120-130
35. Gardulf A., Anderson V., Bjorkander J., et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 345 (1995) 365-369
36. Welch M.J., and Steihm E.R. Slow subcutaneous immunoglobulin therapy in a patient with reactions to IM immunoglobulin. J Clin Immunol 3 (1983) 285-286
37. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 112 (2004) 1-7
38. Gardulf A., Nicolay U., Math D., et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 114 (2004) 936-942
39. Nicolay U., Kiessling P., Berger M., et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 26 (2006) 65-72
40. Kittner J.M., Grimbacher B., Wulff W., et al. Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol 26 (2006) 400-405
41. Busse P.J., Razvi S., and Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 109 (2002) 1001-1004
42. Pirofsky B. Intravenous immune globulin therapy in hypogammaglobulinemia. Am J Med 76 3 (1984) 53-60
43. Ochs H.D., Buckley R.H., Pirofsky B., et al. Safety and patient acceptability of intravenous immune globulin in 10% maltose. Lancet II (1980) 1158-1159
44. Eibl M. Intravenous immunoglobulins: clinical and experimental studies. In: Alving B.M., and Finlayson J.S. (Eds). Immunoglobulins: characteristics and uses of intravenous preparations (1980), US Food and Drug Administration, US Department of Health and Human Services, Bethesda (MD) 23-30
45. Roifman C.M., Levison H., and Gelfand E.W. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1 (1987) 1075-1077
46. Gelfand E.W., Reid B., and Roifman C.M. Intravenous immune serum globulin replacement in hypogammaglobulinemia. A comparison of high- versus low-dose therapy. Monogr Allergy 23 (1988) 177-186
47. Roifman C.M., Schroeder H., Berger M., et al. Comparison of the efficacy of IGIV- C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol 3 (2003) 1325-1333
48. Eijkhout H.W., van Der Meer J.W., Kallenberg C.G., et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinaemia: a randomized, double-blinded, multicenter crossover trial. Ann Intern Med 135 (2001) 165-174
49. Kainulainen L., Varpula M., Liippo, et al. Pulmonary abnormalities in patients with primary hypogammaglobulienaemia. J Allergy Clin Immunol 104 (1999) 1031-1036
50. Busse P.J., Farzan S., and Cunningham-Rundles C. Pulmonary complications of common variable immunodeficiency. Ann Allergy Asthma Immunol 98 (2007) 1-11
51. Berger M. Goals of therapy in antibody deficiency syndromes. J Allergy Clin Immunol 104 (1999) 911-913
52. Ochs H.D., Gupta S., Kiessling P., et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 26 (2006) 265-273
53. In: Sewell W.A.C. (Ed). Sucutaneous IgG therapy medical education programme (2006), Watermeadow PLC, Oxfordshire (UK)
54. Ziegner U.H., Kobayashi R.H., Cunningham-Rundles C., et al. Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment. Clin Immunol 102 (2002) 19-24
55. In: Grabenstein John D. (Ed). ImunoFacts, 2008 (2007), Lippincott, Williams and Wilkins, Philadelphia